A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants
A Phase 1, Single-Center, Open-Label, 3-Cohort, Fixed-Sequence, Drug-Drug Interaction Study To Assess The Pharmacokinetics Of LY4100511 (DC-853) When Orally Administered Alone, When Coadministered With Itraconazole, Fluconazole, Or Carbamazepine In Healthy Adult Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: This is a single site clinical trial 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 13176154559
- Email: ClinicalTrials.gov@lilly.com
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78209
- ICON San Antonio Clinical Research Unit
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have a body mass index within the range of 18.0 to 32 kilograms per square meter (kg/m²)
- Males who agree to follow contraceptive requirements and women of not childbearing potential
- Have body weight greater than or equal to (>=) 50 Kilograms at screening.
- Must have a negative Interferon-Gamma Release Assays (IGRA) testing at screening
- Must have been stopped all the prescribed medication at least 14 days prior to admission to the clinical site
- Ability and willingness to abstain from alcohol, caffeine, and methylxanthine-containing beverages or food 2 days prior to admission to the clinical site
- Abstain from any strenuous physical exercise from 4 days prior to admission and during confinement at the clinical site
Exclusion Criteria:
- Have a history of relevant drug and/or food allergies, or sensitivity to medications used in the current study
- Females participants who are currently breastfeeding
- Have History of alcohol abuse or drug addiction
- Unable to abstain from tobacco products within the 2 days prior to admission and during confinement at the clinical site
- Have Positive screen for hepatitis B surface antigen, hepatitis C virus (HCV) antibodies, or human immunodeficiency virus (HIV) 1 and 2 antibodies
- Consumption of any nutrients known to modulate CYP450 enzymes activity
- Are immunocompromised
- Have received live vaccine(s) (including attenuated live vaccines) or Bacillus Calmette-Guérin within 28 days of screening or intend to receive them during the study
- Have had any malignancy within the past 5 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LY4100511 (DC-853) + Itraconazole
Single oral doses of LY4100511 (DC-853) with single and multiple doses of Itraconazole administered orally.
|
Administered orally.
Administered orally.
Other Names:
|
|
Experimental: LY4100511 (DC-853) + Fluconazole
Single oral doses of LY4100511 (DC-853) with single and multiple doses of fluconazole administered orally.
|
Administered orally.
Other Names:
Administered orally.
|
|
Experimental: LY4100511 (DC-853) + Carbamazepine
Single oral doses of LY4100511 (DC-853) with single and multiple doses of Carbamazepine administered orally.
|
Administered orally.
Administered orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4100511 (DC-853)
Time Frame: Predose up to 26 Days
|
Predose up to 26 Days
|
|
PK: PK: Area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration (AUC[0-t]) of LY4100511 (DC-853)
Time Frame: Predose up to 26 Days
|
Predose up to 26 Days
|
|
PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf]) of LY4100511 (DC-853)
Time Frame: Predose up to 26 Days
|
Predose up to 26 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Contact Lilly at 1-800-LillyRx (1-800-545-5979), Eli Lilly and Company
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Anti-Infective Agents
- Antifungal Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Enzyme Inhibitors
- Central Nervous System Depressants
- Sensory System Agents
- Analgesics, Non-Narcotic
- Analgesics
- Sodium Channel Blockers
- Membrane Transport Modulators
- Tranquilizing Agents
- Psychotropic Drugs
- Steroid Synthesis Inhibitors
- Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Anticonvulsants
- Antimanic Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Itraconazole
- Fluconazole
- Carbamazepine
Other Study ID Numbers
Other Study ID Numbers
- DCE853103 (Other Identifier: DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company)
- J5C-MC-FOAG (Other Identifier: DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.